

CORRECTION

Correction to: Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension

Katsuyoshi Suzuki · Naomi Otsuka · Hiroko Hizaki · Masayo Hashimoto ·

Yasuaki Kuwayama · On behalf of the Tafluprost/Timolol Versus Latanoprost/Timolol (TTVLT) Study Group

Published online: January 8, 2019

© Springer Healthcare Ltd., part of Springer Nature 2019

Correction to: Adv Ther (2018) 35:796–808

<https://doi.org/10.1007/s12325-018-0718-9>

In the original publication, the range to derive the *P* values is incorrectly represented in Tables 2 and 3. The corrected tables are provided below.

The original article can be found online at <https://doi.org/10.1007/s12325-018-0718-9>.

K. Suzuki (✉)
Suzuki Eye Clinic, Yamaguchi, Japan
e-mail: suzuki_eye@grace.ocn.ne.jp

N. Otsuka · H. Hizaki · M. Hashimoto
Santen Pharmaceutical Co., Ltd., Osaka, Japan

Y. Kuwayama
Fukushima Eye Clinic, Osaka, Japan

Table 2 Mean (\pm standard deviation) superficial punctate keratopathy scores (range 0–3)

	TAF/TIM (n=58)	LAT/TIM (n=50) ^a	p-value ^b
Total SPK score			
Week 0	0.7 (0.9)	0.8 (1.1)	0.661
Week 6	0.5 (0.8)	0.8 (1.1)	–
Week 12	0.4 (0.7)	0.7 (1.0)	–
Change from BL at Week 12	–0.2 (0.7)	–0.2 (1.1)	0.240
Superior SPK score			
Week 0	0.1 (0.2)	0.1 (0.2)	0.858
Week 6	0.0 (0.1)	0.1 (0.2)	–
Week 12	0.0 (0.1)	0.1 (0.2)	–
Change from BL at Week 12	0.0 (0.2)	0.0 (0.3)	0.461
Mid SPK score			
Week 0	0.2 (0.5)	0.4 (0.6)	0.040
Week 6	0.2 (0.4)	0.3 (0.6)	–
Week 12	0.2 (0.4)	0.2 (0.4)	–
Change from BL at Week 12	–0.1 (0.4)	–0.2 (0.7)	0.416
Inferior SPK score			
Week 0	0.4 (0.6)	0.4 (0.6)	0.879
Week 6	0.3 (0.6)	0.4 (0.6)	–
Week 12	0.3 (0.5)	0.4 (0.6)	–
Change from BL at Week 12	–0.2 (0.5)	0.0 (0.6)	0.085

Bold indicates significant values

BL baseline, LAT latanoprost, SPK superficial punctate keratopathy, TAF tafluprost, TIM timolol

^a Data missing for one patient in the LAT/TIM group

^b Calculated using Wilcoxon two-sample test

^c Calculated using Wilcoxon one-sample test

Table 3 Mean (\pm standard deviation) tear break-up times and hyperemia scores (range 0–3)

	TAF/TIM (n=58)	LAT/TIM (n=50) ^a	p-value
TBUT, sec			
Week 0	4.13 (1.85)	4.63 (2.49)	0.241 ^b
Week 6	4.27 (2.04)	4.32 (2.79)	–
Week 12	4.32 (2.13)	4.34 (2.67)	–
Change from BL at Week 12	0.19 (2.09)	–0.28 (2.36)	0.274 ^b
Hyperemia score			
Week 0	0.3 (0.5)	0.3 (0.6)	0.722 ^c
Week 6	0.3 (0.5)	0.3 (0.5)	–
Week 12	0.4 (0.5)	0.3 (0.5)	–
Change from BL at Week 12	0.1 (0.3)	0.0 (0.3)	0.445 ^c

BL baseline, *LAT* latanoprost, *TAF* tafluprost, *TBUT* tear breakup time, *TIM* timolol

^a Data missing for one patient in the LAT/TIM group

^b Calculated using *t* test

^c Calculated using Wilcoxon two-sample test

^d Calculated using Wilcoxon one-sample test